ARCHIVES

Arzerra Maintenance Therapy Extends PFS In Phase III Trial, Compared to Observation

This article is from The Cancer Letter archive.

Vol. 37 No. 8 | August 29, 2014

Download PDF Visit The Full Archive

Related Articles

Alan Davis to Retire From ACS; Five Execs Keep Top Positions

September 10, 1993

Capitated Oncology Becomes Marketplace Reality Wit Plan By Companies

January 14, 1994

In Brief: NCAB Objects To Low Priority For Several Cancer Control Grants, Asks For New Review

June 22, 1979

ACS to Being Review Of Facilities Survey Proposals; Working Group Established

May 25, 1984

Cancer Research Faces A “Strategic Inflection,” NCI Director Says

April 19, 2002

Cobimetinib-Zelboraf Therapy Increases OS In BRAF V600 Mutation-Positive Disease

October 31, 2014